On Oct 30, major Wall Street analysts update their ratings for $Sage Therapeutics (SAGE.US)$, with price targets ranging from $4 to $26.
J.P. Morgan analyst Anupam Rama maintains with a hold rating.
TD Cowen analyst Ritu Baral maintains with a hold rating, and maintains the target price at $10.
Mizuho Securities analyst Uy Ear maintains with a hold rating.
Needham analyst Ami Fadia maintains with a hold rating.
RBC Capital analyst Brian Abrahams maintains with a sell rating, and maintains the target price at $4.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Sage Therapeutics has been observed to report third quarter results with notable total revenue, operating expenses, and a cash position that is predicted to extend the company's financial runway into 2026. The disappointing outcome of the SAGE-718 Phase 2 LIGHTWAVE study for patients with Alzheimer's Disease Mild Cognitive Impairment has led to a strategic shift to focus on the development of Zurzuvae and the potential of dalzanemdor for Huntington's Disease Mild Cognitive Impairment, with Phase 2 DIMENSION results anticipated by the end of 2024. Additionally, there is an expectation of relevant updates from Biogen regarding its third quarter in 2024.
Here are the latest investment ratings and price targets for $Sage Therapeutics (SAGE.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月30日，多家华尔街大行更新了$Sage Therapeutics (SAGE.US)$的评级，目标价介于4美元至26美元。
摩根大通分析师Anupam Rama维持持有评级。
TD Cowen分析师Ritu Baral维持持有评级，维持目标价10美元。
瑞穗证券分析师Uy Ear维持持有评级。
Needham分析师Ami Fadia维持持有评级。
加皇资本市场分析师Brian Abrahams维持卖出评级，维持目标价4美元。
此外，综合报道，$Sage Therapeutics (SAGE.US)$近期主要分析师观点如下：
以下为今日9位分析师对$Sage Therapeutics (SAGE.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
